Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Cancer. 2016 Mar 9;122(9):1312–1337. doi: 10.1002/cncr.29936

TABLE 3.

Cancer Incidence Rates for 2008 to 2012 and Fixed-Interval Trends From 2003 to 2012 for the Top Cancers by Sex, Race, and Ethnicity for Areas in the United States With High-Quality Incidence Dataa

Sex/Cancer
Site or Typec 		All Races and Ethnicities
Whiteb
Blackb
APIb
AI/AN (CHSDA)b
Hispanicb
Non-Hispanicb
Rank Rated 2003–
2012
AAPCe 		2008–
2012
AAPCe 		Rank Rated 2003–
2012
AAPCe 		Rank Rated 2003–
2012
AAPCe 		Rank Rated 2003–
2012
AAPCe 		Rank Rated 2003–
2012
AAPCe 		Rank Rated 2003–
2012
AAPCe 		Rank Rated 2003–
2012
AAPCe
All sitesf
 Both sexes 454.0 −0.9g −2.1g 454.5 −0.9g 466.6 −1.2g 292.1 −0.9g 385.6 −1.6g 353.7 −1.3g 464.7 −0.8g
 Men 512.7 −1.7g −3.4g 506.5 −1.6g 573.6 −2.2g 309.7 −1.9g 416.2 −2.8g 400.8 −2.4g 524.1 −1.6g
 Women 412.6 −0.3g −0.8g 418.4 −0.2 394.9 −0.2 283.1   0.2 367.2 −0.4 324.7 −0.5g 422.3 −0.2g
 Children (ages 0–14 years) 16.0   0.5   0.5 16.6   0.4 12.6   0.5 12.8   0.8 11.1 −1.3 15.6 −0.1 16.2   0.6g
 Children (ages 0–19 years) 17.4   0.4g   0.4g 18.2   0.3 13.1   0.3 13.8   1.1 12.6 −0.5 16.8   0.3 17.6   0.5g
Top 17 cancers among men
 Prostate 1 131.5 −3.2g −7.0g 1 121.4 −3.6g 1 205.1 −3.5g 1 67.8 −4.5g 1 90.5 −5.8g 1 112.1 −4.7g 1 133.5 −3.1g
 Lung and bronchus 2 76.7 −2.5g −3.4g 2 76.2 −2.5g 2 91.2 −2.8g 2 47.4 −1.8g 2 66.2 −2.6g 3 43.3 −3.1g 2 79.6 −2.4g
 Colon and rectum 3 48.3 −3.6g −3.6g 3 47.1 −3.8g 3 59.1 −3.5g 3 39.0 −2.6g 3 50.4 −1.9g 2 44.6 −3.0g 3 48.8 −3.6g
 Urinary bladder 4 36.4 −1.1g −1.1g 4 38.6 −1.1g 5 19.5   0.0 6 15.4 −1.0g 6 18.3 −1.9g 5 20.1 −2.3g 4 37.8 −1.0g
 Melanoma of the skin 5 25.4   1.7g   0.6 5 28.4   1.7g 25 1.1 −1.0 20 1.5 −1.7 13 6.8 −1.0 17 4.7 −1.3 5 27.6   2.0g
 Non-Hodgkin lymphoma 6 23.1 −0.7g −1.5g 6 23.7 −0.7g 6 17.0 −0.4 5 15.7   0.2 7 17.0 −2.1 6 19.9 −0.8g 6 23.4 −0.6g
 Kidney and renal pelvis 7 21.5   1.0g −0.5g 7 21.6   1.0g 4 23.6   1.6g 9 10.8   1.3 4 29.7 −1.3 4 20.6   0.6g 7 21.7   1.1g
 Oral cavity and pharynx 8 16.9   0.6g   0.6g 8 17.3   0.9g 9 15.0 −2.5g 8 10.9   0.2 8 14.7   1.1 11 10.9 −0.5 8 17.6   0.8g
 Leukemia 9 16.8 −0.3g −0.3g 9 17.3 −0.4g 12 12.9 −0.1 11 9.6   0.6 11 11.2 −2.5 9 12.7 −0.7 9 17.0 −0.3g
Pancreas 10 14.0   0.8g   0.5g 10 13.8   0.9g 7 16.8   0.0 10 9.8   0.1 10 11.3 −1.1 10 12.0 −0.2 10 14.2   0.9g
 Liver and intrahepatic bile duct 11 11.5   3.5g   2.3g 11 10.3   3.7g 8 16.2   3.9g 4 20.6 −1.3g 5 18.7   3.2 7 19.3   1.8g 11 10.8   3.5g
 Stomach 12 9.3 −1.3g −1.3g 13 8.4 −1.1g 10 14.8 −2.3g 7 14.5 −3.8g 9 12.0 −4.2g 8 13.5 −2.9g 12 8.9 −1.4g
 Esophagus 13 8.3 −1.4g −2.9g 12 8.5 −0.9 14 7.8 −5.3g 15 3.8 −2.2 12 7.2 −0.2 14 5.3 −2.3g 13 8.6 −1.3g
 Brain and other nervous system 14 7.8 −0.7g −1.4g 14 8.3 −0.7g 15 4.8   0.0 14 4.4 −0.5 16 5.3 −0.4 13 5.9 −1.3g 14 8.1 −0.5g
 Myeloma 15 7.7   0.8g   0.8g 16 7.1   0.7g 11 14.6   0.5 13 4.5   0.5 14 6.3 −1.5 12 7.5   0.5 15 7.8   0.8g
 Thyroid 16 6.8   5.2g   2.8g 15 7.3   5.3g 17 3.6   4.6g 12 6.3   6.4g 18 4.0   2.5 16 5.1   5.2g 16 7.1   5.4g
 Larynx 17 6.3 −2.8g −3.6g 18 6.2 −2.5g 13 9.1 −3.9g 18 2.3 −2.0 15 5.8 −2.2 15 5.2 −3.7g 17 6.4 −2.4g
 Top 18 cancers among women
 Breast 1 123.1   0.1   0.1 1 124.2   0.0 1 121.8   0.8g 1 88.3   1.1g 1 91.9 −0.3 1 91.9 −0.1 1 126.6   0.2
 Lung and bronchus 2 54.1 −0.9g −2.2g 2 55.7 −0.9g 2 50.3 −1.0g 3 28.3 −0.1 2 52.7 −0.5 3 26.0 −1.3g 2 56.7 −0.8g
 Colon and rectum 3 36.6 −3.2g −3.8g 3 35.7 −3.2g 3 43.3 −3.6g 2 29.2 −2.6g 3 40.1 −2.3g 2 30.6 −2.8g 3 37.2 −3.1g
 Corpus and uterus, NOS 4 25.3   1.1g   1.1g 4 25.8   1.0g 4 24.3   2.4g 5 17.7   2.3g 4 22.9   1.5 4 21.1   1.6g 4 25.7   1.1g
 Thyroid 5 20.3   5.6g   2.9g 5 21.3   5.6g 6 12.7   5.9g 4 20.4   5.7g 7 12.9   5.2g 5 19.3   5.3g 5 20.6   5.7g
 Non-Hodgkin lymphoma 6 16.0 −1.0g −1.7g 7 16.5 −1.1g 8 11.8 −0.3 6 10.8 −0.1 6 13.5 −3.0g 6 15.2 −0.7 7 16.1 −1.0g
 Melanoma of the skin 7 15.9   1.4g −0.1 6 18.3   1.5 27 1.0 −1.3 21 1.2 −1.4 16 5.2   0.5 18 4.0 −1.7g 6 17.5   1.8g
 Ovaryf 8 11.9 −2.0g −2.0g 8 12.3 −2.1g 11 9.4 −1.3g 7 9.0 −0.9g 8 11.8 −0.3 8 10.6 −2.1g 8 12.0 −2.0g
 Kidney and renal pelvis 9 11.3   0.9g −1.1 9 11.4   1.0g 7 12.7   2.2g 13 4.9   0.1 5 18.3   0.6 7 11.8   1.3g 9 11.3   0.9g
 Pancreas 10 10.9   0.7g   0.7g 11 10.6   0.7g 5 14.2   0.6 8 8.7   1.3g 9 9.6 −1.6 9 10.3   0.3 10 11.0   0.8g
 Leukemia 11 10.3   0.0   0.0 10 10.6 −0.1 12 8.3   0.6 12 6.2   0.5 11 8.9   0.6 11 8.9 −0.1 11 10.3   0.0
 Urinary bladder 12 9.0 −1.4g −1.4g 12 9.5 −1.4g 14 6.6 −0.8g 15 3.8 −1.5 17 4.9   1.6 14 5.1 −2.3g 12 9.4 −1.2g
 Cervix uteri 13 7.7 −1.3g −1.3g 13 7.5 −1.1g 10 9.8 −2.3g 11 6.3 −3.0g 10 9.4 −0.5 10 10.2 −3.9g 13 7.4   1.1g
 Oral cavity and pharynx 14 6.3   0.4g   0.4g 14 6.4   0.7g 15 5.1 −1.2g 14 4.9 −0.6 15 5.2 −1.1 17 4.2   0.2 14 6.6   0.5g
 Brain and other nervous system 15 5.6 −1.0g −1.8g 15 6.1 −0.8g 17 3.5 −0.7 16 3.1 −0.9g 18 3.8   1.6 16 4.5 −1.6g 15 5.8 −0.7g
 Myeloma 16 5.1   0.3   0.5 16 4.4   0.0 9 10.9   0.9g 17 2.9   0.1 14 5.3 −1.8 15 5.1 −0.6 16 5.1   0.4
 Stomach 17 4.6 −0.9g   0.2 17 4.0 −1.0g 13 7.9 −1.2g 9 8.5 −2.8g 13 6.6 −1.4 12 7.8 −2.2g 17 4.3 −1.0g
 Liver and intrahepatic bile duct 18 3.9   3.0g   2.3g 18 3.5   3.6g 16 4.8   3.4g 10 7.9 −1.2 12 8.9   2.2 13 7.2   2.4g 18 3.6   2.9g

Abbreviations: AAPC, average annual percent change; AI/AN, American Indian/Alaska Native; API, Asian/Pacific Islander; CHSDA, Indian Health Service Contract Health Services Delivery Area; NOS, not otherwise specified.

a

Source: National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology, and End Results (SEER) areas reported by the North American Association of Central Cancer Registries (NAACCR) as meeting high-quality incidence data standards for the specified time periods (2008–2012 rates for all races/ethnicities, white, black, AI/AN, API, Hispanic, and non-Hispanic [48 states: Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming]; 2003–2012 AAPCs for all races/ethnicities, white, black, AI/AN, API, Hispanic, and non-Hispanic [45 states: Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming]).

b

White, black, API, and AI/AN (CHSDA 2012 counties) include Hispanic and non-Hispanic; the race and ethnicity categories are not mutually exclusive. AI/AN (CHSDA 2012) statistics exclude data from Kansas.

c

Cancers are listed in descending rank of sex-specific, age-adjusted rates for 2008 through 2012 for all racial and ethnic groups combined. More than 15 cancers may appear under men and women to include the top 15 cancers in each racial and ethnic group.

d

Rates are per 100,000 persons and were age-adjusted to the 2000 US standard population (19 age groups: ages <1 year, 1–4 years, 5–9 years, …, 80–84 years, ≥85 years; Census publication p25-1130 [US Bureau of the Census, Current Population Reports, p25-1130. Washington, DC: US Government Printing Office; 2000]).

e

The AAPC is a weighted average of the annual percent change (APC) calculated by joinpoint analyses with up to 2 joinpoints yielding up to 3 trend segments based on rates per 100,000 persons and age adjusted to the 2000 US standard population (19 age groups; Census publication p25-1130). For the joinpoint analysis, the Joinpoint Regression Program was used (version 4.2.0.0, April 2015; Statistical Research and Applications Branch, National Cancer Institute, Bethesda, MD).

f

For all sites, myelodysplastic syndromes are included for the rate calculations but not for the APC calculations; they are excluded from cancer-specific analyses. Ovary excludes borderline tumors.

g

The AAPC is statistically significantly different from zero (2-sided Z test; P < .05).